PanTracer Portfolio
The PanTracer portfolio reflects our commitment to evolving with the needs of oncology care—offering tests that are practical, powerful, and designed to support real-world clinical decisions.
PanTracer Tissue, PanTracer Tissue + HRD and PanTracer LBx
Next-generation diagnostic solutions for patients with advanced-stage solid tumors.
The PanTracer portfolio empowers oncologists with actionable genomic insights for confident, real-time treatment decisions. Whether you’re selecting approved targeted therapies or exploring clinical trials, working from a liquid or tissue biopsy, PanTracer ensures that you’re equipped with the insights you need.
PanTracer Tissue, the next evolution of Neo Comprehensive - Solid Tumor, offers a tissue-based CGP approach, providing deep insights into tumor genomics from solid-tumor biopsy samples, helping oncologists make precise, actionable therapy decisions.
PanTracer Tissue + HRD is a single, advanced assay designed specifically for advanced ovarian cancer, uniquely combining Comprehensive Genomic Profiling (CGP) and HRD assessment in one streamlined solution.
PanTracer portfolio features
 | Broad, guideline-compliant CGP panels |
 | Rapid turnaround time |
 | Actionable and informative reports |
 | Minimal specimen requirements |
PanTracer Tissue
PanTracer Tissue
In oncology, every decision matters. PanTracer Tissue offers broad, tissue-based CGP designed to support oncologists in delivering personalized care. Aligned with clinical guidelines, this test covers key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment.
- 517 genes, detecting both guideline-recommended and emerging alterations
- DNA + RNA sequencing for optimized fusion detection
- Minimal specimen requirements supporting broader patient access
PanTracer LBx
PanTracer LBx
In the evolving landscape of precision oncology, accessing tumor-specific genomic insights quickly and noninvasively is critical. PanTracer LBx is a liquid biopsy test that delivers comprehensive, clinically actionable insights from a simple blood draw. It empowers real-time decision-making, especially for patients for whom tissue biopsies are not feasible.
- 514 genes, detecting both guideline-recommended and emerging alterations
- High sensitivity, ctDNA sequencing for detection from blood samples
- Minimally invasive CGP results, ideal for patients where tissue testing fails or when tissue is unavailable
PanTracer Tissue + HRD
PanTracer Tissue + HRD
PanTracer Tissue + HRD offers CGP with integrated HRD assessment. Our advanced HRD score assesses BRCA1/2 and tumor genomics instability score (GIS), including loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST), to guide personalized treatment decisions.
With real-time molecular insights, PanTracer Tissue + HRD supports more informed, precise, and effective treatment strategies across the ovarian cancer care continuum.